• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

BerGenBio

Selective AXL inhibitors

  • About BerGenBio
    • About BerGenBio
    • Management Team
    • Board of Directors
    • Partners
  • Pipeline
    • Pipeline overview
    • bemcentinib | NSCLC
    • bemcentinib | COVID-19
    • bemcentinib | Melanoma
    • bemcentinib | AML
    • BGB149
    • BGB601
    • Discovery
    • Publications
    • Expanded access policy
  • Media Centre
    • News
    • Events
    • COVID-19 Media Pack
    • Media Contacts
  • Investors
    • Share Information
    • Largest Shareholders
    • Stock Exchange Notices
    • Presentations
    • Financial Reports
    • Financial Calendar
    • Analysts
    • General Meetings
    • Corporate Governance
    • IR Contacts
  • Careers
  • Contact
Home  /  Investors

Investors

Quarterly Reports

Q3 2020 Report

Tuesday, 17 NovemberOnline

Webcast link: https://channel.royalcast.com/hegnarmedia/#!/hegnarmedia/20201117_1

Dial-in numbers:

NO: +47-21-956342

SE: +46-4-0682-0620

DK: +45 78768490
UK: +44-203-7696819
US: +1 646-787-0157

Pin: 712491

Link to live webcast

Corporate Presentation

SEB Annual Healthcare Seminar 2021

18th January 2021

Read More

Share price


BerGenBio ASA

BGBIO (Norway: Oslo)

Share Price Chart

News

Latest News

BERGENBIO HOSTING VIRTUAL R&D Day TODAY

BERGENBIO PRESENTS PHASE II BEMCENTINIB COMBINATION STUDY IN NSCLC AT annual SITC meeting

BERGENBIO TO PRESENT AT Sachs Annual Biotech in Europe Forum

More News

Scientific Presentations

ASH 2020, Prof. Sonja Loges et al.

6 December 2020

A PhII study of bemcentinib, a first-in-class selective AXL kinase inhibitor, in combination with pembrolizumab, in pts with previouslytreated advanced NSCLC: Updated clinical & translational analysis

Read More

Annual Report 2019


BerGenBio (OSE:BGBIO) is a clinical-stage biopharmaceutical company developing innovative drugs for aggressive diseases, including immune evasive, drug resistant and metastatic cancers.

Our annual report

Events

Upcoming Events

DNB Nordic Healthcare Conference 2020

DNB 5th Annual Nordic-American Life Science Conference

Extraordinary General Meeting

BERGENBIO ASA: Invitation to THIRD quarter 2020 results

BERGENBIO ASA: Invitation to a virtual R&D Day

More Events

Primary Sidebar

  • Investors
    • Share Information
    • Largest Shareholders
    • Stock Exchange Notices
    • Presentations
    • Financial Reports
    • Financial Calendar
    • Analysts
    • General Meetings
    • Corporate Governance
    • IR Contacts

News Subscription

Please remember to confirm your email by clicking on the link provided in the subscription confirmation email.

We will save your name and email address with the sole purpose of sending information regarding our latest news and events. By subscribing to BerGenBio’s newsletter you consent to our Privacy Policy and Terms of Use.

Footer

Key Information

  • Pipeline
  • Investors
  • News
  • Presentations
  • Management Team

Useful Information

  • Privacy Policy
  • Terms of Use
  • Job Applicant Privacy Notice
  • Site Map

Get In Touch

BerGenBio ASA
Company registration number 992 219 688

Jonas Lies vei 91, 5009 Bergen, Norway

www.bergenbio.com

+ 47 559 61 159

Copyright © 2017 BerGenBio ASA. All right reserved. Designed by Utopian Designs